1. 抗体抑制剂
  2. 动物体内抗体
  3. Vopratelimab (Mouse IgG2a)

Vopratelimab (Mouse IgG2a) 

目录号: HY-P99382A 纯度: 97.00%
COA 技术支持

Vopratelimab (Mouse IgG2a) 是一种选择性靶向可诱导 T 细胞共刺激因子 (ICOS) 的单克隆抗体。Vopratelimab (Mouse IgG2a) 的可变区与 Vopratelimab (HY-P99382) 的可变区一致,而恒定区为小鼠 IgG2a 序列。Vopratelimab (Mouse IgG2a) 具有抗肿瘤免疫反应并可增强与 anti-PD-1 (HY-P9902A) 的联合疗效。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务

Vopratelimab (Mouse IgG2a)

Vopratelimab (Mouse IgG2a) Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户

规格 价格 是否有货 数量
1 mg ¥4000
In-stock
5 mg ¥9800
In-stock
10 mg ¥13625
In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

Customer Review

Other Forms of Vopratelimab (Mouse IgG2a):

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

Vopratelimab (Mouse IgG2a) is a monoclonal antibody that selectively targets Inducible CO-Stimulator of T cells (ICOS). The variable region of Vopratelimab (Mouse IgG2a) is consistent with that of Vopratelimab (HY-P99382), while the constant region is of Mouse IgG2a sequence. Vopratelimab (Mouse IgG2a) has antitumor immune response and enhances combinatorial efficacy with anti-PD-1 (HY-P9902A) therapy[1].

体内研究
(In Vivo)

Aducanumab (Mouse IGG2a) (0.25-0.3 mg/kg,腹腔注射,分 4 次给药,分别在 7、10、14 和 17 天) 在 Sa1/N 纤维肉瘤小鼠模型中表现出显著的抗肿瘤活性 (70% 的肿瘤消退),并具有全身长期免疫力[1]
Aducanumab (Mouse IGG2a) (0.25 mg/kg,腹腔注射,分 2 次给药,分别在 6 天和 11 天) 在 B16-SIY 肿瘤小鼠模型中表现出显著的抗肿瘤活性并具有长期保护作用[1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female A/J mice (6-8 weeks old) were injected subcutaneously with Sa1/N cells (1 × 106 cells/mouse) to induce Sa1/N fibrosarcoma mice model[1].
Dosage: 0.25-0.3 mg/kg
Administration: i.p., 4 doses (7, 10, 14 and 17 days) for 11 days after tumors reaching approximately 100 mm3.
Result: Had significant anti-tumor activity with 7 out of 10 mice showing complete tumor regression.
Induced systemic long-term immunity with re-challenge with Sa1/N tumors ~45 days after the last treatment in Tumor-free mice.
Decreased the percentage of intratumoral CD4+FoxP3+ Treg within CD3+ cells, but increased in the CD8: Treg and CD4 Teff: Treg ratios in the tumors.
Animal Model: Mice were injected subcutaneously with B16-SIY cells to induce B16-SIY tumor mice model[1].
Dosage: 0.25 mg/kg
Administration: i.p., 6 and 11 days
Result: Induced no tumor growth and survived re-challenge with B16-SIY tumors 10 weeks.
Induced T cells proliferation in both peripheral blood and spleen and tetramer+ T cells proliferation in spleen as well as the frequency of activated memory CD8 T cells.
Induced Treg depletion and increased effector T cell to Treg ratios.
分子量

146.67 kDa

性状

液体

颜色

Colorless to light yellow

运输条件

Shipping with dry ice.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

纯度 & 产品资料
参考文献
  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称:

 

* 需求量:

* 客户姓名:

 

* Email:

* 电话:

 

* 公司或机构名称:

   留言给我们:

Bulk Inquiry

Inquiry Information

产品名称:
Vopratelimab (Mouse IgG2a)
目录号:
HY-P99382A
需求量: